Tag:
Salix Pharmaceuticals
Latest Headlines
Latest Headlines
Salix snags two new drugs in $300M Oceana buyout
Salix is snapping up Oceana Therapeutics for $300 million. Oceana has a pair of drugs on the market: Deflux, which is used to treat vesicoureteral reflux, a bladder problem known to trigger severe
FDA officially denies IBD indication for Salix drug
Salix Pharmaceuticals didn't win the FDA's blessing to market Xifaxan as a remedy for irritable bowel syndrome, a potentially lucrative new use for the drug, which is now approved for traveler's
FDA 'sucker punches' Salix with Xifaxan denial
Salix Pharmaceuticals took a body blow from FDA, as the agency refused to broaden use of its bowel drug Xifaxan. Widely expected to win an indication for use in irritable bowel syndrome, Xifaxan is
Salix licenses new cancer detection tech in $130M pact
Salix Pharmaceuticals has agreed to pay up to roughly $130 million for the licensing rights to a new imaging technology that can be used to spot precancerous lesions in the colon. Doctors currently
Salix shares surge on Xifaxan approval
Shares of Raleigh, NC-based Salix Pharmaceuticals got a nice bounce after the FDA approved its drug Xifaxan for recurrent hepatic encephalopathy, a disease that can trigger memory loss, confusion and
Salix wins FDA panel backing on Xifaxan
Shares of Salix reversed course in after-market trading yesterday evening, shooting up after the developer handily won an FDA expert panel vote backing the safety and efficacy of Xifaxan 550 mg
Salix braces for harsh panel review of Xifaxan
Salix Pharmaceuticals is headed for its scheduled showdown today with a panel of FDA experts who are expected to grill the company on Xifaxan (rifaximin), a drug that is being prepped for the hepatic
Salix shares surge on promising pivotal data
Shares of Salix Pharmaceuticals (SLXP) jumped 35 percent in premarket trading after the company announced that its two late-stage trials for a new therapy for non-constipation irritable bowel
Salix mounts search for 64 new reps
They're hiring! Salix Pharmaceuticals, a Raleigh, NC-based drugmaker, is gearing up for a concerted assault on the market for ulcerative colitis and bowel cleansing meds, with plans to add some 64
FDA experts turn thumbs down on Debiovision drug
An FDA advisory panel unanimously decided to show Debiovision the door after deciding that an experimental drug it was proposing lacked the data it needed to prove the therapy stopped esophageal
